SLC16A7

Across TCGA pan-cancer cohorts, SLC16A7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC16A7 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC16A7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC16A7 expression acts as an unfavorable survival marker.

LSCC and CCRCC are the cancer types where SLC16A7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.538	0.823	.018	8	view →
CCRCC	DFS	Median	II,III,IV	0.577	0.819	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC16A7–LSCC (DFS)

Open the LSCC breakdown →